Although there are currently no specific preventive recommendations for carriers of germline pathogenic variants in the MRN complex genes, this may change when meta-analyses or analyses in unselected cancer populations (e.g., carriers of NBN germline alterations with prostate cancer) are performed. This evidence concerns the gene NBN and Familial prostate cancer.